Skip to content

Price / book at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
2.5×+0.9×
Beam Therapeutics logo
Beam TherapeuticsBEAM
2.1×+0.4×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
+0.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+1.3×

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's price / book?
Intellia Therapeutics (NTLA) reported price / book of 2.4× in Q1 2026.
How has Intellia Therapeutics's price / book changed year-over-year?
Intellia Therapeutics's price / book increased by 158.5% year-over-year, from 0.9× to 2.4×.
What is the long-term trend for Intellia Therapeutics's price / book?
Over 5 years (2020 to 2025), Intellia Therapeutics's price / book has grown at a -27.4% compound annual growth rate (CAGR), from 7.7× to 1.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.